Literature DB >> 16750235

Inhibition of viral assembly in murine cells by HIV-1 matrix.

Wolfgang Hübner1, Benjamin K Chen.   

Abstract

In human cells, the N-terminal matrix (MA) domain of the human immunodeficiency virus type 1 (HIV-1) Gag targets assembly to specific membrane compartments. In murine fibroblasts, membrane targeting of Gag and assembly of HIV-1 are inefficient. These deficiencies are relieved by replacement of HIV-1 MA with murine leukemia virus (MLV) MA in chimeric proviruses. In this study, we examined chimeric HIV-1 carrying tandem MLV and HIV-1 MA domains and found that the addition of MLV MA to the N-terminus of HIV-1 Gag enhanced membrane binding in murine cells, but was not sufficient to stimulate virus production. Removal of HIV MA was required to observe more efficient Gag processing and increased virus production in murine cells. Deletion of the globular head of MA also alleviated the blocks to membrane binding and Gag processing in murine cells, yet did not lead to increased virus production. These MA-dependent, cell-type-specific phenotypes suggest that host factors interact with the globular head of MA to regulate membrane binding and additional membrane-independent step(s) required for assembly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750235     DOI: 10.1016/j.virol.2006.04.024

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Analysis of human immunodeficiency virus matrix domain replacements.

Authors:  Isabel Scholz; Amelia Still; Tenzin Choesang Dhenub; Kelsey Coday; Mike Webb; Eric Barklis
Journal:  Virology       Date:  2007-11-08       Impact factor: 3.616

2.  Isolation and characterization of mouse-human microcell hybrid cell clones permissive for infectious HIV particle release.

Authors:  Ayse K Coskun; Marc van Maanen; David Janka; David Stockton; Pawel Stankiewicz; Pawel Stankiewicsz; Svetlana Yatsenko; Richard E Sutton
Journal:  Virology       Date:  2007-01-31       Impact factor: 3.616

3.  Replication of equine infectious anemia virus in engineered mouse NIH 3T3 cells.

Authors:  Baoshan Zhang; Ronald C Montelaro
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

4.  Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain.

Authors:  Vineela Chukkapalli; Seung J Oh; Akira Ono
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

5.  HIV-1 matrix dependent membrane targeting is regulated by Gag mRNA trafficking.

Authors:  Jing Jin; Timothy Sturgeon; Ora A Weisz; Walther Mothes; Ronald C Montelaro
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

6.  Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses.

Authors:  Ping Chen; Wolfgang Hübner; Matthew A Spinelli; Benjamin K Chen
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

7.  Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1.

Authors:  Wolfgang Hübner; Ping Chen; Armando Del Portillo; Yuxin Liu; Ronald E Gordon; Benjamin K Chen
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

8.  Inability of human immunodeficiency virus type 1 produced in murine cells to selectively incorporate primer formula.

Authors:  Min Wei; Yiliang Yang; Meijuan Niu; Laurie Desfosse; Robert Kennedy; Karin Musier-Forsyth; Lawrence Kleiman
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

Review 9.  Retroviral matrix and lipids, the intimate interaction.

Authors:  Elise Hamard-Peron; Delphine Muriaux
Journal:  Retrovirology       Date:  2011-03-07       Impact factor: 4.602

10.  Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells.

Authors:  Jing-xin Zhang; Gretchen E Diehl; Dan R Littman
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.